Bloom logo

Bloom Health Partners Reports Profitable Fiscal Year 2021 with $9.8 Million in Revenue

Results show a strong first fiscal year, with $5.5 million in cash and continued growth from operations

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a global platform for operational health, is pleased to announce performance for the Company's 2021 fiscal year ended September 30th, 2021.

Business Highlights in Fiscal 2021:

  • Completed reverse takeover with resulting listing on the Canadian Securities Exchange
  • Closed a private placement of $1,278,600 in May 2021
  • Completed acquisition of Round Hill Health Partners LLC in July 2021
  • Successfully integrated acquired operations and consolidated results in fiscal Q4, 2021
  • Completed 2021 fiscal year on September 30th, reporting revenue of $9,843,767 and Adjusted EBITDA(1) of $2,399,626

Fiscal 2021 Summary:

Financial information is reported in Canadian dollars and in accordance with International Financial Reporting Standards (IFRS), unless otherwise stated. The Company achieved revenues from the acquisition date of July 14, 2021 to September 30, 2021 of $9,843,767 and Adjusted EBITDA(1) of $2,399,626. Bloom's cash on hand at the end of Fiscal 2021 is $5,598,296.

In the first half of 2021, prior to the acquisition date, Round Hill Health Partners LLC, achieved $11,888,654 USD in revenues with $5,507,998 USD of net income in the first six calendar months of 2021, as reported in the Business Acquisition Report filed in connection with the acquisition and available under the profile for Bloom on SEDAR (www.sedar.com).

"We're thrilled with the results of our first full fiscal year," said Andrew Morton, CEO of Bloom. "As an Operational Health provider, we've set the stage to deliver successful Occupational Health Programs on our digital platform. Our business with film/TV productions, Fortune 500 companies and state school systems is providing a path to further expanding services and client base in 2022 and beyond. We're already showing growth since completion of fiscal 2021, with two recently announced state school contracts in Texas and Alabama, which are part of a US Government US$10 billion school testing program. We continue to advance discussions with other large organizations and look forward to updating the market as this progresses. Bloom has a strong management team and proven operations that are the foundation for growth by providing innovation in health and health-tech for large organizations."

Financial Statements and Management's Discussion and Analysis

For further details and analysis of our results, please refer to our annual audited financial statements and management's discussion and analysis for the year ended September 30, 2021, available on SEDAR at www.sedar.com.

Non-IFRS Financial Measures

We believe that providing certain non-IFRS financial measures provide users with important information regarding the operational performance of our business. The non-IFRS financial measures used by management do not have any standardized meaning prescribed by IFRS and therefore may not be comparable to similar measures presented by other issuers. Accordingly, these measures should not be considered as a substitute or alternative for IFRS measures as determined in accordance with IFRS. By considering these measures in combination with the comparable IFRS financial measures, we believe that users are provided a better overall understanding of our business and financial performance during the relevant period than if they considered the IFRS financial measures alone.

EBITDA and Adjusted EBITDA

EBITDA is defined as earnings before interest, income taxes, depreciation, and amortization and is utilized by management to assess and evaluate the financial performance of its operations. Management believes that EBITDA improves comparability between periods by eliminating the impact of interest, income taxes, depreciation, and amortization.

Adjusted EBITDA excludes items that are not considered to be indicative of operational and financial trends either by nature or amount to provide a better overall understanding of the Company's underlying business performance. The most directly comparable GAAP measure to EBITDA and Adjusted EBITDA is net income before tax, calculated as follows:



For the year ended September 30

20212020
Net income before tax$149,452
$(416,109)
Amortization of intangibles
679,493

-
Depreciation
32,397

-
Interest expense
249,181

2,159
EBITDA
1,110,523

(413,950)
Listing expense
1,328,871

-
Gain on debt settlement
(39,768)
-
Adjusted EBITDA$2,399,626
$(413,950)

About Bloom Health Partners Inc.

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) is a global platform for healthcare security, diagnostic testing and occupational health-tech. Our mission is to ensure that "unstoppable is possible" for businesses and their employees through innovative, customized healthcare models. Bloom offers a system for businesses and organizations that helps engage employees and creates strategies to manage health and safety. Our stable, scalable system is an integrated health-tech platform that securely manages data while delivering comprehensive workplace health and safety outcomes.

For more information: investors@bloomhealthpartners.com

On behalf of the board of directors,

Bloom Health Partners Inc.

Andrew Morton, Chief Executive Officer

Forward-Looking Statements

This news release includes forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in the Company's forward-looking statements include the potential that milestones may not be satisfied, acquisitions may not achieve expected benefits, financing requirements, and the other risk factors described in the Company's filings with Canadian securities regulators on www.sedar.com. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.


(1) This is a non-IFRS measure. Refer to the section "Non-IFRS Financial Measures" for information on the calculation of these non-IFRS measures.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/112117

News Provided by Newsfile via QuoteMedia

BLMH:CNX
The Conversation (0)
Bloom Health Partners Announces Leadership Transition

Bloom Health Partners Announces Leadership Transition

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of diagnostic and health technology services, announces a leadership transition.

Effective September 30, 2022, Andrew Morton has stepped down as CEO of the Company to pursue other opportunities. Rosemary Elliston, COO of the Company, has been appointed to the position of Interim CEO. Mr. Morton will continue to support the Company as a Director.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Bloom Health Partners Announces New Location in Hawaii

Bloom Health Partners Announces New Location in Hawaii

New Bloom lab will support operations in the Honolulu area and surrounding region

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces the opening of a new location in in the Honolulu area.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Bloom Health Partners CEO to Speak at Health Benefits Nation Conference in Orlando

Bloom Health Partners CEO to Speak at Health Benefits Nation Conference in Orlando

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces its CEO, Andrew Morton, will speak on a panel at Health Benefits Nation Conference in Orlando, Florida on September 15th, 2022.

Mr. Morton will join co-panelists Eric Hargan, former U.S. Federal Deputy Secretary of the Department of Health and Human Services (DHHS), and Jeff Hogan, President of Upside Health Advisors. The panel titled "Incorporating Occupational Health into Value Based Health Strategies" will focus on workplace health and using data models to improve outcomes in occupational health in such areas as preventive care and mental health.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Bloom Health Partners Reports Profitable Fiscal Q3 2022 with $8.4 Million in Revenue

Bloom Health Partners Reports Profitable Fiscal Q3 2022 with $8.4 Million in Revenue

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces unaudited Fiscal Q2 2022 revenues of CAD $8.4M for the three months ended June 30th, 2022, bringing year-to-date revenues to CAD $24.9M for the first three quarters of Fiscal 2022.

Highlights in Fiscal Q2 2022:

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Bloom Health Partners Announces New Location to Serve Chicago and Surrounding Area

Bloom Health Partners Announces New Location to Serve Chicago and Surrounding Area

New Bloom lab in the Chicago area will serve as a foothold in the midwestern United States

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D84) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces the opening of a new location in the Chicago area.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Bausch Health to Announce First-Quarter 2024 Results on May 2

Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call

Conference Call Details

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, LTD. et al v. Norwich Pharmaceuticals, Inc., affirmed the May 17, 2023 decision of the U.S. District Court for the District of Delaware that had denied Norwich Pharmaceuticals, Inc.'s motion for modification of the court's final order preventing the U.S. Food and Drug Administration (FDA) from approving its abbreviated new drug application (ANDA) for XIFAXAN (rifaximin) 550 mg before Oct. 2, 2029. The Court of Appeals also affirmed the August 10, 2022 decision of the District Court that invalidated certain U.S. Patents protecting the composition and use of XIFAXAN® for treating IBS-D. As a result of the Federal Circuit's decision, Norwich's abbreviated new drug application for XIFAXAN (rifaximin) 550 mg remains barred from approval by the U.S. Food and Drug Administration until Oct. 2, 2029

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Acne Vulgaris Treatment PrARAZLO Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that its topical prescription treatment for acne vulgaris, PrARAZLOTM (tazarotene lotion, 0.045% ww), is now available to patients through BC PharmaCare, the public drug program of British Columbia

ARAZLO is the only tazarotene lotion treatment approved by Health Canada for the topical treatment of acne vulgaris in patients 10 years of age and older.1 The listing by BC PharmaCare means ARAZLO is now available to patients on all public drug plans across Canada.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cleo Diagnostics

CLEO Appoints CRO to Manage U.S. Ovarian Cancer Clinical Trials

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to announce the appointment of international Contract Research Organization (CRO), Lindus Health, as a key partner for its U.S. clinical trials program.

Keep reading...Show less

Medtronic unveils the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care

AI-driven solutions and strategic alliances showcase Medtronic's promise to enhance the efficiency and effectiveness of endoscopy

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system, along with a strategic collaboration designed to enhance patient care.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024, at 10:30 a.m. ET at the Metro Toronto Convention Centre in Toronto. A copy of the presentation will be available at www.knighttx.com .

About Knight Therapeutics Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×